Patents Examined by Carlos Azpuru
  • Patent number: 10898618
    Abstract: Amorphous SiOx (SiO2), SiONx, silicon nitride (Si3N4), surface treatments are provided, on both metal (titanium) and non-metal surfaces. Amorphous silicon-film surface treatments are shown to enhance osteoblast and osteoblast progenitor cell bioactivity, including biomineral formation and osteogenic gene panel expression, as well as enhanced surface hydroxyapatite (HA) formation. A mineralized tissue interface is provided using the amorphous silicon-based surface treatments in the presence of osteoblasts, and provides improved bone cell generation/repair and improved interface for secure attachment/bonding to bone. Methods for providing PEVCD-based silicon overlays onto surfaces are provided. Methods of increasing antioxidant enzyme (e.g., superoxide dismutase) expression at a treated surface for enhanced healing are also provided.
    Type: Grant
    Filed: September 8, 2015
    Date of Patent: January 26, 2021
    Assignees: THE TEXAS A&M UNIVERSITY SYSTEM, BOARD OF REGENTS, UNIVERSITY OF TEXAS SYSTEM, UT-BATTELLE, LLC
    Inventors: Venu Varanasi, Pranesh Aswath, Megen Maginot, Nickolay V. Lavrick
  • Patent number: 10897907
    Abstract: Aspects of this disclosure pertain to a colorless material that includes a carrier, copper-containing particles, and quaternary ammonium. In one or more embodiments, the material exhibits, in the CIE L*a*b* system, an L* value in the range from about 91 to about 100, and a C* value of less than about 7, wherein C* equals ?(a*2+b*2). In some embodiments, the material exhibits a greater than 3 log reduction in a concentration of Staphylococcus aureus, under the EPA Test Method for Efficacy of Copper Alloy as a Sanitizer testing conditions.
    Type: Grant
    Filed: December 18, 2019
    Date of Patent: January 26, 2021
    Assignee: CORNING INCORPORATED
    Inventors: Joydeep Lahiri, Florence Christine Monique Verrier
  • Patent number: 10888602
    Abstract: The disclosure provides, among other things, compositions that bind to and inhibit the biological activity of soluble biomolecules, as well as pharmaceutical compositions thereof. Also provided herein are a number of applications (e.g., therapeutic applications) in which the compositions are useful.
    Type: Grant
    Filed: August 7, 2019
    Date of Patent: January 12, 2021
    Assignee: NaNotics, LLC
    Inventor: Louis Hawthorne
  • Patent number: 10881608
    Abstract: Biocompatible intraocular implants include a tyrosine kinase inhibitor and a biodegradable polymer that is effective to facilitate release of the tyrosine kinase inhibitor into the vitreous of an eye for an extended period of time. The therapeutic agents of the implants may be associated with a biodegradable polymer matrix, such as a matrix that is substantially free of a polyvinyl alcohol. The implants can be placed in an eye to treat or reduce the occurrence of one or more ocular conditions.
    Type: Grant
    Filed: September 10, 2018
    Date of Patent: January 5, 2021
    Assignee: ALLERGAN, INC.
    Inventors: Jeffrey L. Edelman, Patrick M. Hughes, Thomas C. Malone, Gerald W. DeVries, Joan-En Chang-Lin, Jane-Guo Shiah, Thierry Nivaggioli, Lon T. Spada, Wendy M. Blanda
  • Patent number: 10881592
    Abstract: Stable suspension compositions including cucurbiturils. More particularly, the stable suspension compositions including cucurbituril particles suspended in a medium. Also, the preparation of the suspension composition and a method of counteracting malodour including application of the suspension composition to a source of malodour.
    Type: Grant
    Filed: August 11, 2017
    Date of Patent: January 5, 2021
    Assignee: AQDOT LIMITED
    Inventors: Roger Coulston, David Diec, Andrew Michael Howe, Jose Martinez-Santiago
  • Patent number: 10881111
    Abstract: The present invention provides a composition of long-term constant-concentration aqueous chlorine dioxide solution including dissolved chlorine dioxide, a decomposition inhibitor for dissolved chlorine dioxide, and a pH modifier, and a method for preparing the same.
    Type: Grant
    Filed: November 26, 2019
    Date of Patent: January 5, 2021
    Assignees: NEOCL Co., Ltd.
    Inventors: Yong Jun Kim, Jung Hyuck Cho
  • Patent number: 10881740
    Abstract: A composition and methods of use and preparation are provided. The composition may comprise a magnetic nanoparticle comprising: a passivation layer; and at least one unique entity that is attached to the magnetic nanoparticle. For example, the composition may include a magnetic nanoparticle and an antibody attached to the magnetic nanoparticle. Such magnetic nanoparticle architecture can provide treatment by, and screening of, nanoparticles functionalized with various functional species.
    Type: Grant
    Filed: June 9, 2020
    Date of Patent: January 5, 2021
    Assignee: Verily Life Sciences LLC
    Inventors: Zhan Wang, Nicole Peck
  • Patent number: 10874598
    Abstract: Compositions and methods are disclosed for repairing damaged keratin fibers or otherwise strengthening keratin fibers, including hair of the human scalp, and particularly hair that has been damaged chemically, physically, thermally or by other means. The compositions comprise 3,3?-thiodipropionic acid (TDPA) or a derivative thereof in a cosmetically acceptable vehicle.
    Type: Grant
    Filed: November 2, 2017
    Date of Patent: December 29, 2020
    Assignee: Avon Products, Inc.
    Inventors: Sen Yang, Allwyn Colaco, Michael J. Fair
  • Patent number: 10874606
    Abstract: An implant for insertion through a punctum and into a canalicular lumen of a patient. The implant includes a matrix of material, a therapeutic agent dispersed in the matrix of material, a sheath disposed over a portion of the matrix of material and configured to inhibit the therapeutic agent from being released from the matrix of material into the canalicular lumen and to allow the therapeutic agent to be released from a surface of the matrix of material to a tear film, and a retention structure configured to retain the implant within the canalicular lumen.
    Type: Grant
    Filed: August 19, 2019
    Date of Patent: December 29, 2020
    Assignee: Mati Therapeutics Inc.
    Inventors: Eugene de Juan, Jr., Stephen Boyd, Cary Reich, Alan Rapacki, Hanson S. Gifford, Mark Deem
  • Patent number: 10869912
    Abstract: Provided are spray-dried thrombin powders comprising microcapsules, methods of preparation and uses thereof.
    Type: Grant
    Filed: November 8, 2018
    Date of Patent: December 22, 2020
    Assignee: Omrix Biopharmaceuticals Ltd.
    Inventors: Erez Ilan, Assaf Gershonovitch, Rivka Kaufman
  • Patent number: 10864218
    Abstract: Biocompatible intraocular implants include a prostamide component and a biodegradable polymer that is effective in facilitating release of the prostamide component into an eye for an extended period of time. The prostamide component may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. The implants may be placed in an eye to treat or reduce a at least one symptom of an ocular condition, such as glaucoma.
    Type: Grant
    Filed: June 24, 2019
    Date of Patent: December 15, 2020
    Assignee: ALLERGAN, INC.
    Inventor: Patrick M. Hughes
  • Patent number: 10857267
    Abstract: An absorbable iron-based alloy implantable medical device includes an iron-based alloy matrix, a degradable polymer coating disposed on the surface of the iron-based alloy matrix, and a corrosion inhibition layer disposed on the surface of the iron-based alloy matrix. The corrosion inhibition layer can delay early-stage corrosion of the iron-based alloy matrix, ensure mechanical performance of a medical device in the early stage of the implantation, prevent degradation of a polymer in the early stage of the implantation of the medical device, and reduce the usage of the degradable polymer, thereby reducing risks of inflammatory reactions.
    Type: Grant
    Filed: June 8, 2016
    Date of Patent: December 8, 2020
    Assignee: LIFETECH SCIENTIFIC (SHENZHEN) CO., LTD
    Inventors: Wenjiao Lin, Li Qin, Deyuan Zhang, Hongtao Sun, Gui Zhang
  • Patent number: 10849843
    Abstract: A cosmetic ink composition comprises a particulate material, a (meth)acrylic acid homopolymer or salt thereof, and a rheology modifier. The particulate material can have a Particle Size Distribution D50 of about 100 nm to about 2,000 nm. The (meth)acrylic acid homopolymer or salt thereof can have a weight average molecular weight of less than about 20,000 daltons. The rheology modifier can be selected from the group consisting of alkali swellable emulsion polymers, hydrophobically modified alkali swellable emulsion polymers, and combinations thereof. The cosmetic ink composition can have a first dynamic viscosity of greater than about 1,100 cP at a shear rate of 0.1 sec?1 measured at 25° C. and a second dynamic viscosity of less than about 100 cP at a shear rate of 1,000 sec?1 measured at 25° C.
    Type: Grant
    Filed: January 31, 2019
    Date of Patent: December 1, 2020
    Assignee: The Procter & Gamble Company
    Inventors: Janette Villalobos Lingoes, Thomas Elliot Rabe, Matthew Joseph Linser, Ajay Suthar
  • Patent number: 10849927
    Abstract: Covalently cross-linked copolymers are described herein. More specifically, polysaccharide-polyamine copolymeric matrices or structures and cationic copolymeric matrices are described herein. The polysaccharide-polyamine copolymers, when protonated, can form cationic copolymeric matrices having exceptionally high densities of cationic sites. In one form, the covalently cross-linked copolymers provide a three-dimensional structure, especially when hydrated.
    Type: Grant
    Filed: March 18, 2016
    Date of Patent: December 1, 2020
    Assignee: HOWARD UNIVERSITY
    Inventors: James W. Mitchell, Dazhi Yang
  • Patent number: 10849848
    Abstract: Compositions comprising electro-activated aqueous solutions and methods for the prevention and treatment of dysfunctional cardiovascular conditions are provided.
    Type: Grant
    Filed: August 31, 2017
    Date of Patent: December 1, 2020
    Assignee: REVEN PHARMACEUTICALS INC.
    Inventors: Henk Van Wyk, Mariette Van Wyk, Trace Krebs, Peter Lange, Brian Denomme, Michael A. Volk
  • Patent number: 10849989
    Abstract: A process for the preparation of a composite comprising a carrier particle and a plurality of drug nanoparticles. The process comprises providing a suspension of drug nanoparticles in the presence of a carrier particle, the carrier particle having an external surface that is functionalised with a surface treatment agent. The process simplifies isolation of drug nanoparticles from suspension.
    Type: Grant
    Filed: September 7, 2017
    Date of Patent: December 1, 2020
    Assignee: University of Limerick
    Inventors: Sarah Hudson, Teresa Tierney, Ake Rasmuson, Katalin Bodnar
  • Patent number: 10842754
    Abstract: Non-viral delivery platforms are provided for facilitating transport of molecules across cell membranes. In some forms, DNA nanoshells capable of transporting cargo molecules are formed, and may be formed in order to surround a variety of materials for a variety of purposes.
    Type: Grant
    Filed: December 1, 2017
    Date of Patent: November 24, 2020
    Assignee: HOWARD UNIVERSITY
    Inventor: Preethi Chandran
  • Patent number: 10842755
    Abstract: A nanoparticle suitable for delivery of an active agent across the blood-brain barrier is provided. As such, the nanoparticle can target brain tissue so that the active agent can be delivered across the blood-brain barrier to the target brain tissue. The nanoparticle includes a core that includes a core material such as a polymer or inorganic material as well as an active agent; and a shell comprising a membrane derived from a brain metastatic cancer cell, wherein the brain metastatic cancer cell facilitates transport of the nanoparticle across a blood-brain barrier. Also disclosed are methods of forming the nanoparticle and methods of using the nanoparticle.
    Type: Grant
    Filed: February 19, 2019
    Date of Patent: November 24, 2020
    Assignee: University of South Carolina
    Inventor: Peisheng Xu
  • Patent number: 10835556
    Abstract: Described herein are hydrolyzed tetravalent salts and formulations thereof that can be used to inhibit a biofilm. Also described herein are uses of the hydrolyzed tetravalent salts and formulations thereof to inhibit a biofilm and/or treat biofilm infection.
    Type: Grant
    Filed: February 28, 2019
    Date of Patent: November 17, 2020
    Assignee: Board of Trustees of the University of Illinois
    Inventor: Russell Pesavento
  • Patent number: 10828265
    Abstract: Melts or ionic liquids containing amorphous propranolol, topical formulations and patches for transdermal drug delivery, and methods of making and using thereof are described herein. The melts or ionic liquids may be in a topical drug delivery formulation or patch to be applied to the skin. The drug delivery formulation or patch contains a sufficient amount of the amorphous propranolol to deliver a therapeutically effective amount of the amorphous propranolol to the patient in need of treatment, such as for the treatment or amelioration of infantile hemangioma. The formulations have a low viscosity and reduced skin irritation compared to the crystalline propranolol free base (PFB). The melts or ionic liquids can be formed by a salt metathesis reaction.
    Type: Grant
    Filed: December 11, 2017
    Date of Patent: November 10, 2020
    Assignee: The Regents of the University of California
    Inventors: Kazuhiro Aoyagi, Michael Zakrewsky, Samir Mitragotri